1. Introduction

Intrauterine contraception is convenient, safe and highly efficacious, and is recommended as a first-line option for all women, including adolescent and nulliparous women. It is available as either copper-containing intrauterine devices (CU-IUDs) or a levonorgestrel intrauterine system (LNG-IUS).

The Mirena LNG-IUS has been the only intrauterine system licensed available in Spain until recently. Since 2013, Jaydess has been in the market and it has shown good results.

Jaydess differentiates from Mirena in levonorgestrel content (13.5 mg vs 52 mg, respectively), years of contraceptive use (3 years vs 5 years, respectively), a smaller frame, a narrower inserter tube, and other characteristics and effects.

The effectiveness of Jaydess has been demonstrated in Phase II and Phase III studies that showed good Pearl indexes (which measures the effectiveness of a birth control method) and low Insler scores (cervical mucus score).

Despite lower serum levels of LNG with Jaydess (average, ~8 g/24 hours during the first year), there is no evidence that suggests any clinical significant advantage in terms of side effects. What studies have shown in favor of Jaydess, is a high overall user satisfaction rate in adolescents (83.9% at 12 months) and adult women (95% at the end of 3 years).

Because of being a relatively newly contraceptive method, we conducted this survey to acknowledge the safety, comfort and satisfaction with the use and continuation of Jaydess in our population.

2. Materials and methods.

This was a prospective observational study conducted at a private clinic of gynecology, obstetric and reproductive medicine services. All healthy women aged 18-40 years old with regular menses requesting contraception were recruited. Participants who decided to use the LNG-IUS were included. A survey was given and complimented at 1 week, 1 month, 6 months and a year after placement of the LNG-IUS. A different survey was filled in case of retirement of the LNG-IUS. Results. A total of 114 women participated in the study. After a whole year of use, 95% of women were satisfied of choosing the LNG-IUS as their contraceptive method and more than 90% of all women stated that they wouldn’t choose other contraceptive method with a 95% of women willing to recommend its use.

Conclusion. The LNG-IUS is a good and safety option for contraceptive method in women despite their parity and age.
Participants had a total of seven scheduled visits to the clinic: a screening visit, placement visit, and five visits at months 1, 3, 6, 9 and 12, after placement. A survey was given and complimented at 1 week, 1 month, 6 months and a year after placement of the LNG-IUS. A different survey was filed in case of retirement of the LNG-IUS. Satisfaction was assessed using five-point Likert-type scales and was taken from the most recent survey received from each subject for both continuers and discontinuers. The electronic medical record was used to clarify subjective data when necessary.

Data were analyzed using Microsoft Excel and GraphPad software. We used descriptive statistics and for categorical data, Fisher’s exact test was performed using a p<0.05 to determine significance.

3. Results.
A total of 114 women participated in the study (see table 1). All women completed at least three study surveys and 112 completed the whole study. Mean age was 32.63 (range 26-40) years. More than 86% of women had completed professional or degree studies and the rest had finished compulsory education. Race/ethnicity was recorded as a hundred percent Caucasian women.

For pain symptoms related to insertion see Figure 1. The majority of women reported none or mild pain during insertion (68.41%) and none or mild lightheadedness and nausea, and another 10.54% more severe symptoms (see table 2).

After a whole year of use, 95% of women were satisfied of choosing the LNG-IUS as their contraceptive method (see figure 2-B) and more than 90% of all women stated that they wouldn’t choose another contraceptive method.

4. Discussion.
Our study contributes to the premise that intra-uterine contraception is safe and well tolerated not only in multiparous women but in nulliparous as well. Also, we obtained important information about experiences of women related to: the insertion procedure; one, six and 12 months of IUD use; that can be used for patient and provider information and education.

Our sample size is relatively small, but compared with the overall experience in other clinics in Spain; it provides a good estimation for both continuers and discontinuers. The electronic medical record was used to clarify subjective data when necessary.

Overall the insertion procedure was well tolerated. There are some studies reporting a widely ranging pain scores from 2.7 to 6.8 out of 10 in nulliparous women (Allen, Carey, Raker, Goyal, & Matteson, 2014; Brown & Trouton, 2014; Dijkstra et al., 2011; Espey et al., 2014). These variations can be attributed to a variation of pain scores and are frequently inconsistent between populations (Hall & Kutler, 2016). We assessed the pain with categorical variables and not only a 7% reporting this symptom in the survey. Sixty-one percent of women reported mild cramps during their period and only 21% indicated pain with intercourse.

After six-months of use over 75% women reported to be “very satisfied” and “satisfied” for choosing the LNG-IUS as their contraceptive method (Figure 2-A). Less than 10% referred dissatisfaction and almost 90% of women wouldn’t choose another contraceptive method.

After one month of LNG-IUS insertion, more than a half of women reported irregular periods (83.15%) with around 70% indicating less flow, spotting or even no menstrual flow. Only 9% of those women used another contraceptive method but half of these patients used condoms because of risk for sexually transmitted diseases. Almost 40% of women reported mild cramps during their period and only 21% indicated pain with intercourse.

More than a half women reported regular periods after six months of use with only 10% indicating heavy bleeding. Seven women needed combined oral contraceptives because of spotting and cramps during period reduce to less than 30% of patients. Only 13% reported pain during intercourse.

Figures

For pain symptoms related to insertion see Figure 1. The majority of women reported none or mild pain during insertion (68.41%) and none or mild lightheadedness and nausea, and another 10.54% more severe symptoms (see table 2).

After six months of use over 75% women reported to be “very satisfied” and “satisfied” for choosing the LNG-IUS as their contraceptive method (Figure 2-A). Less than 10% referred dissatisfaction and almost 90% of women wouldn’t choose another contraceptive method.
shown that there is no intervention that has been effective in reducing pain during IUD insertion (misoprostol [Espey et al., 2014; Ward, Jacobson, Turok, & Murphy, 2011], topical lidocaine [Allen, Raker, & Goyal, 2013; A. L. Nelson & Fong, 2013], ibuprofen [Hubacher et al., 2006]) so we attributed our relatively lower pain scores to: a) parity; and b) size of the IUD when compared to copper IUD.

When assessing effectiveness, a Phase III RCT including 1432 Jaydess users, has demonstrated a Pearl index of 0.41 (95% CI 0.13-0.96) at 1 year and a cumulative Pearl index after 3 years’ use of 0.33 pregnancies per 100 woman-years (95% CI 0.16-0.60) (A. Nelson et al., 2013). The Kaplan-Meier estimate for the cumulative failure rate of Jaydess over 3 years was 0.9% (A. Nelson et al., 2013). We didn’t have any pregnancies reported, but our sample is relatively small and our follow-up was limited to one year only.

The most common reasons for method-related discontinuations of the LNG-IUS are usually unacceptable bleeding patterns and hormonal side effects including: acne, mood changes and a decreased libido (Hall & Kutler, 2016). We found that the reason for discontinuation in our population was attributed to bleeding patterns. However, our findings showed that more than a half of women reported regular menstrual patterns after six-months of use, and more than 60% after a whole year of Jaydess use. This is similar to what has been reported by other authors in that there is a lower rate of amenorrhea in Jaydess users when compared with other methods such as Mirena (Gemzell-Danielsson et al., 2012). When a whole year has passed, the spotting or abnormal bleeding seemed to reduce and this could be the reason for a high satisfaction among users.

Jaydess is good contraceptive option because of many advantages: a) it is a long-acting reversible contraceptive; b) although amenorrhea may occur, Jaydess may appeal to women who prefer to have regular bleeding patterns; c) the smaller dimensions of Jaydess when compared to other IUD may conferred an advantage in terms of easy fitting and reduced pain scores associated with insertion.

Our study contributes to expand the literature regarding safety and comfort for the LNG-IUS. If providers and patients are better informed about symptoms and experiences, not only in terms of the insertion procedure but also during months of use, it is easy to help counseling, take a decision and, most important, to have a good overall satisfaction that provides higher continuation rates.

5. Conclusion. Our survey indicates that the LNG-IUS Jaydess is a good and safety option for contraceptive method in women despite their parity and age. It is safe, effective and well tolerated and has higher satisfaction and continuation rates.

6. REFERENCES: